Home > Insider Trading > Filing (0001181431-11-023874)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
716646	Clinical Data Inc	CLDA	Pharmaceutical Preparations (2834)	042573920

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
38074	Forest Laboratories Inc	909 Third Avenue New York NY 10022	No	No	Yes	No
1513956	Magnolia Acquisition Corp.	C/O Forest Laboratories, Inc. 909 Third Avenue New York NY 10022	No	No	Yes	No
1514018	C.v. Holding Fl	C/O Forest Laboratories, Inc. 909 Third Avenue New York NY 10022	No	No	Yes	No
1514019	Fli International, Llc	C/O Forest Laboratories, Inc. 909 Third Avenue New York NY 10022	No	No	Yes	No
1516557	Dogwood Holding Corp.	C/O Forest Laboratories, Inc. 909 Third Avenue New York NY 10022	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-04-12	27,868,256	$30.00	0	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	2005 Warrants	Acquisiton	2011-04-12	93,556	$14.90	108,850	$15.60
Common Stock	2006 Warrants	Acquisiton	2011-04-12	113,817	$17.71	143,774	$12.97
Common Stock	2008 Warrants	Acquisiton	2011-04-12	757,461	$13.56	757,461	$16.44
Common Stock	Series A 2009 Warrants	Acquisiton	2011-04-12	1,527,650	$21.88	1,527,650	$8.12
Common Stock	Series B 2009 Warrants	Acquisiton	2011-04-12	1,527,650	$20.26	1,527,650	$9.74
Common Stock	2017 Convertible Notes	Acquisiton	2011-04-12	6,110,599	$30.00	6,110,599	$8.18

Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2005-11-17	2011-05-17	No	4	P	Direct
2006-06-13	2011-12-14	No	4	P	Direct
2008-09-26	2014-03-26	No	4	P	Direct
2009-02-25	2014-08-25	No	4	P	Direct
2009-02-25	2014-08-25	No	4	P	Direct
2009-02-25	2014-08-25	No	4	P	Direct

Footnotes

This form is filed on behalf of Forest Laboratories, Inc. ("Forest"), FL Holding C.V. ("FL Holding"), FLI International LLC ("FLI International"), Dogwood Holding Corp. ("Dogwood") and Magnolia Acquisition Corp. ("Magnolia"), all of which are filing as members of a 10% owner group. Forest is the direct parent of FL Holding, and the indirect parent of FLI International and Dogwood. FLI International is the general partner of FL Holding, and FL Holding is the parent of Dogwood. Pursuant to the terms of the Merger Agreement, Magnolia was merged with and into Clinical Data on April 13, 2011. Prior to the merger, Magnolia was a wholly-owned subsidiary of Dogwood.
The price of each security also includes the contractual right, pursuant to a Contingent Value Rights Agreement, dated as of April 13, 2011, by and among FL Holding, Forest and American Stock Transfer & Trust Company, LLC, as Rights Agent, to receive additional consideration of up to $6.00 per share upon the achievement of certain milestones related to Viibryd?? (the "CVR consideration").
All of Clinical Data's outstanding securities were cancelled and/or exercised in a merger of Magnolia with and into Clinical Data on April 13, 2011 pursuant to the Merger Agreement, and converted into the right to receive the $30.00 in cash and the CVR Consideration.
The 2017 Convertible Notes may be repaid at any time upon 90 days prior written notice. The final maturity date of the 2017 Convertible Notes is February 25, 2017.